Literature DB >> 7859668

Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection.

A A Rodriquez1, C N Ford, D M Bless, R L Harmon.   

Abstract

Electromyographic (EMG) evidence of inappropriate muscle activity (IMA) in the cricothyroid (CT) and vocalis (V) (thyroarytenoid) muscles was correlated with clinical voice measures in 32 patients with spasmodic dysphonia (SD). Subjective voice rating and quantified fluency and laryngeal diadochokinesis measures were obtained prior to botulinum toxin (Botox) injection into the V muscles. Pre-Botox EMG was performed using a monopolar needle electrode. Each muscle was sequentially examined at rest, during vocal click, scale, sustained "E" at different pitches, and repeated "E" voicings for brief periods. A three point EMG severity scale was used to grade the amount of IMA seen in each muscle. EMG evaluation showed no evidence of lower motor neuron involvement but did reveal IMA in 81.3% of the subjects. There were no significant correlations for the patients between different EMG-based IMA severity scales and the measures of voice quality and sound production. EMG did discriminate between predominantly adductor and abductor SD pattern types, but could not correctly differentiate a mixed SD group. Those patients with adductor SD displayed IMA in the V and CT muscles, while those with abductor SD displayed more IMA in the CT than the V muscles. Sequential EMG assessment of CT and V IMA in SD did not predict clinical severity or outcome following Botox injection into the V muscles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859668

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  4 in total

1.  Vocal outcome after endoscopic thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia.

Authors:  Sachin Gandhi; Marc Remacle; Prasun Mishra; Vrushali Desai
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-12       Impact factor: 2.503

Review 2.  Spasmodic dysphonia: a laryngeal control disorder specific to speech.

Authors:  Christy L Ludlow
Journal:  J Neurosci       Date:  2011-01-19       Impact factor: 6.167

Review 3.  Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.

Authors:  C R Watts; D D Truong; C Nye
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

Review 4.  Botulinum toxin injections for the treatment of spasmodic dysphonia.

Authors:  C C W Watts; R Whurr; C Nye
Journal:  Cochrane Database Syst Rev       Date:  2004
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.